Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
12
1
2020
medline:
3
3
2021
entrez:
12
1
2020
Statut:
ppublish
Résumé
The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new scenarios and novel challenges in the diagnosis and management of a number of novel immune-related adverse events. Among these, immune checkpoint inhibitor-induced pancreatic injury has been described (occurring in up to 4% of patients) and has been reported to be responsible for visits to the emergency departments in up to 1.9% of patients treated with immune checkpoint inhibitors. This side effect can be symptomatic or non-symptomatic, and can be associated with the development of long-term damage to the pancreas, requiring the involvement of different specialists, including radiologists and gastroenterologists in the multidisciplinary team that manages these patients. The aim of this narrative review is to provide a summary of the available literature related to immune checkpoint inhibitor-induced pancreatic injury including the epidemiology, the clinical findings, and the management algorithm for diagnosis with a detailed analysis of the differential diagnosis at imaging, and treatment. A more in-depth focus is dedicated to symptomatic acute pancreatitis with its peculiar findings at imaging (ultrasound, computed tomography, and magnetic resonance imaging).
Identifiants
pubmed: 31925647
doi: 10.1007/s11523-019-00694-w
pii: 10.1007/s11523-019-00694-w
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-35Références
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):165. https://doi.org/10.1038/s12276-018-0191-1 .
doi: 10.1038/s12276-018-0191-1
pmcid: 6292890
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0 .
doi: 10.1038/s41571-019-0218-0
pubmed: 31092901
Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–73. https://doi.org/10.1038/s41379-018-0013-y .
doi: 10.1038/s41379-018-0013-y
pubmed: 29403081
Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38:13–9. https://doi.org/10.1200/EDBK_100013.Review .
doi: 10.1200/EDBK_100013.Review
pubmed: 30231401
Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiologic features. Cancers. 2019;11(3):305. https://doi.org/10.3390/cancers11030305 .
doi: 10.3390/cancers11030305
pmcid: 6468855
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17. https://doi.org/10.1200/JCO.2016.68.2005 .
doi: 10.1200/JCO.2016.68.2005
pubmed: 27646942
Zhou W, Huang Y, Lai J, Lu J, Feely M, Liu X. Anti-inflammatory biologics and anti-tumoral immune therapies-associated colitis: a focused review of literature. Gastroenterology Res. 2018;11(3):174–88. https://doi.org/10.14740/gr1041w .
doi: 10.14740/gr1041w
pubmed: 29915627
pmcid: 5997479
Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, et al. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018;45(3):181–6. https://doi.org/10.1053/j.seminoncol.2018.09.002 .
doi: 10.1053/j.seminoncol.2018.09.002
pubmed: 30352754
Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol. 2017;120:13–211. https://doi.org/10.1016/j.critrevonc.2017.09.017 .
doi: 10.1016/j.critrevonc.2017.09.017
pubmed: 29198327
Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, et al. Radiologic evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? Crit Rev Oncol Hematol. 2018;126:135–44. https://doi.org/10.1016/j.critrevonc.2018.03.026 .
doi: 10.1016/j.critrevonc.2018.03.026
pubmed: 29759556
Hlavata Z, Solinas C, De Silva P, Porcu M, Saba L, Willard-Gallo K, et al. The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? Target Oncol. 2018;13(2):113–23. https://doi.org/10.1007/s11523-018-0556-3 .
doi: 10.1007/s11523-018-0556-3
pubmed: 29470785
Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2016;5(11):59. https://doi.org/10.1007/s40134-017-0256-2 .
doi: 10.1007/s40134-017-0256-2
pubmed: 28959504
Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92. https://doi.org/10.1158/2326-6066.CIR-15-0102 .
doi: 10.1158/2326-6066.CIR-15-0102
pubmed: 26100356
pmcid: 4596761
Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7(1):31. https://doi.org/10.1186/s40425-019-0502-7 .
doi: 10.1186/s40425-019-0502-7
pubmed: 30728076
pmcid: 6364483
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. https://doi.org/10.1182/blood-2017-06-741033 .
doi: 10.1182/blood-2017-06-741033
pubmed: 29118008
Solinas C, Aiello M, Gu-Trantien C, De Silva P, Migliori E, Willard-Gallo K, et al. Targeting PD-1 in cancer: biological insights with a focus on breast cancer. Crit Rev Oncol Hematol. 2019;142:35–433. https://doi.org/10.1016/j.critrevonc.2019.07.011 .
doi: 10.1016/j.critrevonc.2019.07.011
pubmed: 31357142
NCCN guidelines 2019 - Management of Immune Checkpoint Inhibitor-Related Toxicities, Version 2.2019. https://www.nccn.org/professionals/physician_gls/default.aspx#supportive . Accessed 8 Apr 2019.
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225
doi: 10.1093/annonc/mdx225
pubmed: 28881921
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 27 Nov 2017.
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98. https://doi.org/10.1038/nrclinonc.2013.153 .
doi: 10.1038/nrclinonc.2013.153
pubmed: 23982524
Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics. 2017;37(7):2132–44. https://doi.org/10.1148/rg.2017170085 .
doi: 10.1148/rg.2017170085
pubmed: 29131763
Yoneda S, Imagawa A, Hosokawa Y, Baden MY, Kimura T, Uno S, et al. T-Lymphocyte Infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors. Diabetes Care. 2019;42(7):e116–e11818. https://doi.org/10.2337/dc18-2518 .
doi: 10.2337/dc18-2518
pubmed: 31076419
George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology. 2019;19(4):587–94. https://doi.org/10.1016/j.pan.2019.04.015 .
doi: 10.1016/j.pan.2019.04.015
pubmed: 31076344
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.xlsx Accessed 14 June 2010.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80. https://doi.org/10.2337/dbi18-0002 .
doi: 10.2337/dbi18-0002
pubmed: 29937434
pmcid: 6054443
Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res. 2018;6(12):1453–8. https://doi.org/10.1158/2326-6066.CIR-17-0659 .
doi: 10.1158/2326-6066.CIR-17-0659
pubmed: 30275274
El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med. 2019;73(1):79–877. https://doi.org/10.1016/j.annemergmed.2018.04.019 .
doi: 10.1016/j.annemergmed.2018.04.019
pubmed: 29880440
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. https://doi.org/10.3389/fphar.2017.00049 .
doi: 10.3389/fphar.2017.00049
pubmed: 28228726
pmcid: 5296331
La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35(10):963–76. https://doi.org/10.1002/phar.1643 .
doi: 10.1002/phar.1643
pubmed: 26497482
Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–9. https://doi.org/10.1200/JCO.2014.60.0379 .
doi: 10.1200/JCO.2014.60.0379
pubmed: 25918278
pmcid: 4881375
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48. https://doi.org/10.1016/j.ejca.2015.11.016 .
doi: 10.1016/j.ejca.2015.11.016
pubmed: 26765102
Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015. https://doi.org/10.14694/EdBook_AM.2015.35.76
doi: 10.14694/EdBook_AM.2015.35.76
pubmed: 25993145
Friedman CF, Clark V, Raikhel AV, et al. Thinking Critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst. 2016;109(4):djw260. doi:10.1093/jnci/djw260
doi: 10.1093/jnci/djw260
Kiriyama S, Gabata T, Takada T, Hirata K, Yoshida M, Mayumi T, et al. New diagnostic criteria of acute pancreatitis. J Hepatobiliary Pancreat Sci. 2010;17(1):24–36. https://doi.org/10.1007/s00534-009-0214-3 .
doi: 10.1007/s00534-009-0214-3
pubmed: 20012328
Johnson CD, Besselink MG, Carter R. Acute pancreatitis. BMJ. 2014;349:g4859. https://doi.org/10.1136/bmj.g4859 .
doi: 10.1136/bmj.g4859
pubmed: 25116169
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11. doi: 10.1136/gutjnl-2012–302779
Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010;139(3):813–20. https://doi.org/10.1053/j.gastro.2010.06.010 .
doi: 10.1053/j.gastro.2010.06.010
pubmed: 20540942
Busireddy KK, AlObaidy M, Ramalho M, et al. Pancreatitis-imaging approach. World J Gastrointest Pathophysiol. 2014;5(3):252–70. https://doi.org/10.4291/wjgp.v5.i3.252 .
doi: 10.4291/wjgp.v5.i3.252
pubmed: 25133027
pmcid: 4133524
Bollen TL. Acute pancreatitis: international classification and nomenclature. Clin Radiol. 2016;71(2):121–33. https://doi.org/10.1016/j.crad.2015.09.013 .
doi: 10.1016/j.crad.2015.09.013
pubmed: 26602933
Foster BR, Jensen KK, Bakis G, Shaaban AM, Coakley FV. Revised atlanta classification for acute pancreatitis: a pictorial essay. Radiographics. 2016;36(3):675–87. https://doi.org/10.1148/rg.2016150097 .
doi: 10.1148/rg.2016150097
pubmed: 27163588
Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35(2):424–37. https://doi.org/10.1148/rg.352140121 .
doi: 10.1148/rg.352140121
pubmed: 25763727
Dehghani L, Mikail N, Kramkimel N, Soyer P, Lebtahi R, Mallone R, et al. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment. Eur J Cancer. 2018;104:243–6. https://doi.org/10.1016/j.ejca.2018.09.014 .
doi: 10.1016/j.ejca.2018.09.014
pubmed: 30454710
Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012;262(3):751–64. https://doi.org/10.1148/radiol.11110947 .
doi: 10.1148/radiol.11110947
pubmed: 22357880
Badea R. Ultrasonography of acute pancreatitis—an essay in images. Rom J Gastroenterol. 2005;14(1):83–9.
pubmed: 15800700
Baker ME, Nelson RC, Rosen MP, Blake MA, Cash BD, Hindman NM, et al. ACR Appropriateness criteria® acute pancreatitis. Ultrasound Q. 2014;30(4):267–73. https://doi.org/10.1097/RUQ.0000000000000099 .
doi: 10.1097/RUQ.0000000000000099
pubmed: 25364960
Drake LM, Anis M, Lawrence C. Accuracy of magnetic resonance cholangiopancreatography in identifying pancreatic duct disruption. J Clin Gastroenterol. 2012;46(8):696–9. https://doi.org/10.1097/MCG.0b013e31825003b3 .
doi: 10.1097/MCG.0b013e31825003b3
pubmed: 22565603
Manikkavasakar S, AlObaidy M, Busireddy KK, et al. Magnetic resonance imaging of pancreatitis: an update. World J Gastroenterol. 2014;20(40):14760–77. https://doi.org/10.3748/wjg.v20.i40.14760 .
doi: 10.3748/wjg.v20.i40.14760
pubmed: 25356038
pmcid: 4209541
Xiao B, Zhang XM. Magnetic resonance imaging for acute pancreatitis. World J Radiol. 2010;2(8):298–308. https://doi.org/10.4329/wjr.v2.i8.298 .
doi: 10.4329/wjr.v2.i8.298
pubmed: 21160684
pmcid: 2999333
Barral M, Taouli B, Guiu B, Koh DM, Luciani A, Manfredi R, et al. Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology. 2015;274(1):45–63. https://doi.org/10.1148/radiol.14130778 .
doi: 10.1148/radiol.14130778
pubmed: 25531479
Balci NC, Alkaade S, Magas L, Momtahen AJ, Burton FR. Suspected chronic pancreatitis with normal MRCP: findings on MRI in correlation with secretin MRCP. J Magn Reson Imaging. 2008;27(1):125–31.
doi: 10.1002/jmri.21241
pubmed: 18058927
Choueiri NE, Balci NC, Alkaade S, Burton FR. Advanced imaging of chronic pancreatitis. Curr Gastroenterol Rep. 2010;12(2):114–20. https://doi.org/10.1007/s11894-010-0093-4 .
doi: 10.1007/s11894-010-0093-4
pubmed: 20424983
Perez-Johnston R, Sainani NI, Sahani DV. Imaging of chronic pancreatitis (including groove and autoimmune pancreatitis). Radiol Clin North Am. 2012;50(3):447–66. https://doi.org/10.1016/j.rcl.2012.03.005 .
doi: 10.1016/j.rcl.2012.03.005
pubmed: 22560691
Majumder S, Takahashi N, Chari ST. Autoimmune pancreatitis. Dig Dis Sci. 2017;62(7):1762–9. https://doi.org/10.1007/s10620-017-4541-y .
doi: 10.1007/s10620-017-4541-y
pubmed: 28365915
Zhang L, Chari S, Smyrk TC, Deshpande V, Klöppel G, Kojima M, et al. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteria. Pancreas. 2011;40(8):1172–9. https://doi.org/10.1097/MPA.0b013e318233bec5 .
doi: 10.1097/MPA.0b013e318233bec5
pubmed: 21975436
Madhani K, Farrell JJ. Autoimmune pancreatitis: an update on diagnosis and management. Gastroenterol Clin North Am. 2016;45(1):29–43. https://doi.org/10.1016/j.gtc.2015.10.005 .
doi: 10.1016/j.gtc.2015.10.005
pubmed: 26895679
Madhani K, Farrell JJ. Management of autoimmune pancreatitis. Gastrointest Endosc Clin N Am. 2018;28(4):493–519. https://doi.org/10.1016/j.giec.2018.05.002 .
doi: 10.1016/j.giec.2018.05.002
pubmed: 30241640
Lee LK, Sahani DV. Autoimmune pancreatitis in the context of IgG4-related disease: review of imaging findings. World J Gastroenterol. 2014;20(41):15177–89. https://doi.org/10.3748/wjg.v20.i41.15177 .
doi: 10.3748/wjg.v20.i41.15177
pubmed: 25386067
pmcid: 4223252
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International association of pancreatology. international consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40(3):352–8. doi: 10.1097/MPA.0b013e3182142fd2
doi: 10.1097/MPA.0b013e3182142fd2
pubmed: 21412117
Dickerson LD, Farooq A, Bano F, Kleeff J, Baron R, Raraty M, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging. World J Surg. 2019;43(6):1604–11. https://doi.org/10.1007/s00268-019-04928-w .
doi: 10.1007/s00268-019-04928-w
pubmed: 30815742
Saba L, Biswas M, Kuppili V, Cuadrado Godia E, Suri HS, Edla DR, et al. The present and future of deep learning in radiology. Eur J Radiol. 2019;114:14–24. https://doi.org/10.1016/j.ejrad.2019.02.038 .
doi: 10.1016/j.ejrad.2019.02.038
pubmed: 31005165